Ester Pro-drugs for Alpha-2 Adrenergic Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions for alpha 2 adrenergic receptor modulation lack effective delivery mechanisms for treating a wide range of conditions, including pain, glaucoma, and neurodegenerative diseases, with limited bioavailability and sustained action.
Innovation Solution
Development of ester pro-drugs of (S) [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, which undergo hydrolytic or enzymatic cleavage to release the active metabolite, providing improved bioavailability and sustained action through various delivery forms such as topical eye drops, injectable formulations, and sustained release devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ester pro-drugs are used to improve bioavailability and sustained action, then therapeutic effectiveness is improved, but molecular complexity increases
Solution Approach 1:
The ester pro-drug acts as an intermediary compound that is metabolically converted to the active alpha-2 adrenergic agonist in vivo. The pro-drug structure includes an ester group that is hydrolyzed by esterases to release the active metabolite, thereby improving bioavailability and enabling sustained action while maintaining a relatively simple molecular structure
Solution Approach 2:
The invention modifies the pharmacokinetic parameters of the active compound by introducing an ester pro-drug moiety. This changes the absorption, distribution, metabolism, and excretion characteristics of the drug, enabling improved bioavailability and sustained release profiles without fundamentally altering the core pharmacophore structure
2Duration of action of moving object
If pro-drug design is used to enable sustained release, then duration of action is improved, but metabolic pathway complexity increases
Solution Approach 1:
The ester pro-drug utilizes the body's endogenous esterase enzymes to achieve sustained release of the active metabolite. The pro-drug structure is designed to be progressively hydrolyzed by ubiquitous esterases in plasma and tissues, creating a self-sustaining release mechanism that leverages existing biological pathways rather than requiring complex external delivery systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ester pro-drugs offer enhanced bioavailability and sustained action, effectively modulating alpha 2 adrenergic receptors to treat a broad spectrum of conditions, including pain, glaucoma, and neurodegenerative diseases, with improved therapeutic outcomes.
Implementation Method 1
Upon hydrolytic or enzymatic cleavage of the ester functionality the parent compound, active metabolite, (S) -[3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, is released
Data Source
AI summary
The present invention relates to novel compounds, ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors.